Takeda has entered into a global collaboration and licensing agreement with Halozyme that gives it exclusive access to the ENHANZE drug delivery technology for vedolizumab.[1][3] Vedolizumab is a biologic drug used to treat ulcerative colitis and Crohn's disease and is sold globally under the name ENTYVIO.[2][4] ENHANZE technology utilizes the enzyme rHuPH20 and is designed to facilitate the subcutaneous administration of injectable drugs, which can shorten administration time and simplify treatment.[1][3][4] According to Halozyme, the ENHANZE technology has been used in more than ten commercialized products and has reached more than one million patients in over 100 countries.[1][3][2] The deal was completed in December 2025 and announced on January 8, 2026.[1][4] Under the financial terms, Takeda will pay Halozyme an upfront fee, potential future development and commercial milestone payments, and Halozyme will receive royalties from sales of products containing vedolizumab in combination with ENHANZE.[2][3][4]